Australia Nuclear Medicine Market Size & Outlook
Australia nuclear medicine market, 2018-2030 (US$M)
Related Markets
Australia nuclear medicine market highlights
- The Australia nuclear medicine market generated a revenue of USD 200.8 million in 2023 and is expected to reach USD 391.6 million by 2030.
- The Australia market is expected to grow at a CAGR of 10% from 2024 to 2030.
- In terms of segment, diagnostics was the largest revenue generating product in 2023.
- Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
Nuclear medicine market data book summary
| Market revenue in 2023 | USD 200.8 million |
| Market revenue in 2030 | USD 391.6 million |
| Growth rate | 10% (CAGR from 2023 to 2030) |
| Largest segment | Diagnostics |
| Fastest growing segment | Therapeutics |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
Other key industry trends
- In terms of revenue, Australia accounted for 2.0% of the global nuclear medicine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan nuclear medicine market is projected to lead the regional market in terms of revenue in 2030.
- Singapore is the fastest growing regional market in Asia Pacific and is projected to reach USD 187.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nuclear Medicine Market Scope
Nuclear Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia nuclear medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 73.21% in 2023. Horizon Databook has segmented the Australia nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Australia is considered to be one of the top six manufacturers of radioisotopes in the world. It has been estimated that the OPAL reactor provided 15% of the global supply of Mo-99 radiopharmaceuticals in 2018. About 80.0% of radioisotopes produced in the OPAL reactor are used for diagnostic purposes, while the remaining are used for therapeutic purposes.
This reactor produces radioisotopes to meet the growing demand in the country, as well as to export them to nearby countries in the Asia Pacific region. The Australian Nuclear Science Technology Organization (ANSTO) is trying to find a solution for the disposal of nuclear waste.
Furthermore, the company is undertaking initiatives to boost local manufacturing of radiopharmaceuticals, which will fuel market growth. For instance, in July 2019, ANSTO received TGA approval to manufacture F-18 for clinical trials.
Reasons to subscribe to Australia nuclear medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia nuclear medicine market databook
-
Our clientele includes a mix of nuclear medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into Australia nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia nuclear medicine market size, by product, 2018-2030 (US$M)
Australia Nuclear Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
